{"success":true,"data":{"pressRelease":{"id":"169551","rtpr_id":"nPnbfTd6qa-20261014","ticker":"ELVN","exchange":"NASDAQ","all_tickers":["ELVN"],"title":"Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year","author":"PR Newswire","published_at":"2026-10-14T20:30:01.487Z","article_body":"Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year\nPR Newswire\n\nBURLINGAME, Calif., Oct. 14, 2026\n\nAccomplished biopharmaceutical executive with extensive experience in\ncorporate strategy, finance and commercial readiness\n\nEnliven continues preparation for late-stage development and\ncommercialization, as it plans to initiate the pivotal Phase 3 trial of\nrelcobatinib before year-end\n\nBURLINGAME, Calif., Oct. 14, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=651038477&u=https%3A%2F%2Fwww.enliventherapeutics.com%2F&a=Enliven+Therapeutics%2C+Inc.)\n(Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical\ncompany focused on the discovery and development of small molecule\ntherapeutics, today announced the appointment of Kristine Ball to its Board of\nDirectors, effective immediately. Ms. Ball brings more than 20 years of\nexecutive experience across clinical-stage and commercial-stage\nbiopharmaceutical companies.\n\n\"We are pleased to welcome Kristine Ball to our Board,\" said Rick Fair, Chief\nExecutive Officer of Enliven. \"Her experience helping companies transition\nfrom clinical development to commercial operations will bring valuable\nperspective as we prepare to initiate our pivotal Phase 3 trial of\nrelcobatinib before year-end and plan for commercialization. We look forward\nto her contributions as we work to deliver a differentiated treatment option\nfor people living with chronic myeloid leukemia and create long-term value for\nour shareholders.\"\n\n\"Having seen the impact of CML on a member of my family, I feel a personal\nconnection to Enliven's mission of helping people with CML not only live\nlonger, but live better,\" said Ms. Ball. \"I'm excited to contribute as the\nCompany navigates this transition and prepares for potential\ncommercialization. I look forward to working with the Board and leadership\nteam to help advance relcobatinib through pivotal development and prepare\nEnliven for its next stage of growth.\"\n\nMs. Ball brings extensive executive leadership and financial expertise in the\nbiotechnology industry. Her experience spans corporate strategy, financing,\ncommercial readiness and corporate governance.  She has served as Chief\nExecutive Officer of Antiva Biosciences; Chief Executive Officer of Soteria\nBiotherapeutics; Senior Vice President of Corporate Strategy and Chief\nFinancial Officer of Menlo Therapeutics; and Senior Vice President and Chief\nFinancial Officer of Relypsa, where she helped guide the company's transition\nfrom clinical development to commercial operations. Additionally, she serves\non the Board of Directors of Oruka Therapeutics, where she chairs the Audit\nCommittee. She previously served on the boards of Atreca and Forty Seven. Ms.\nBall earned a Bachelor of Science from Babson College.\n\nFollowing its recent announcement of FDA alignment on the final design of\nENABLE-2, Enliven remains focused on initiating the pivotal Phase 3 trial of\nrelcobatinib (ELVN-001) in patients with previously treated chronic myeloid\nleukemia (CML) before year-end 2026.\n\nAbout Enliven Therapeutics\nEnliven is a clinical-stage biopharmaceutical company focused on the discovery\nand development of small molecule therapeutics to help people not only live\nlonger, but live better. Enliven aims to address existing and emerging unmet\nneeds with a precision medicine approach that improves survival and enhances\noverall well-being. Enliven's discovery process combines deep insights into\nclinically validated biological targets and differentiated chemistry to design\npotentially first-in-class or best-in-class therapies. Enliven is based in\nBurlingame, California. To learn more, visit www.enliventherapeutics.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=2498345477&u=http%3A%2F%2Fwww.enliventherapeutics.com%2F&a=www.enliventherapeutics.com)\nand connect with us on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=3197493944&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4745046-1%26h%3D2856687620%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fenliventherapeutics%26a%3DLinkedIn&a=LinkedIn)\n and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=810257792&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4745046-1%26h%3D3997352174%26u%3Dhttps%253A%252F%252Fx.com%252FEnliven_Tx%26a%3DX&a=X)\n.\n\nForward-Looking Statements\nThis press release contains forward-looking statements (including within the\nmeaning of Section 21E of the Securities Exchange Act of 1934, as amended, and\nSection 27A of the Securities Act of 1933, as amended) concerning Enliven and\nother matters that involve substantial risks and uncertainties. These\nstatements may discuss goals, intentions and expectations as to future plans,\ntrends, events, results of operations and financial condition, or otherwise,\nbased on current beliefs of Enliven's management, as well as assumptions made\nby, and information currently available to, Enliven's management.\nForward-looking statements generally include statements that are predictive in\nnature and depend upon or refer to future events or conditions, and include\nwords such as \"may,\" \"will,\" \"should,\" \"would,\" \"expect,\" \"anticipate,\"\n\"plan,\" \"likely,\" \"believe,\" \"estimate,\" \"project,\" \"intend,\" and other\nsimilar expressions or the negative or plural of these words, or other similar\nexpressions that are predictions or indicate future events or prospects,\nalthough not all forward-looking statements contain these words. Statements\nthat are not historical facts are forward-looking statements. Forward-looking\nstatements in this press release include, but are not limited to: statements\nregarding the potential of, and plans regarding, market opportunities,\ncommercial readiness, potential commercialization, and expectations regarding\nrelcobatinib (ELVN-001); statements regarding the potential differentiated\nattributes and therapeutic benefit of relcobatinib; the continued conduct,\ndesign and future clinical evaluation of relcobatinib, including the planned\nENABLE-2 Phase 3 trial and the potential timing of initiation of ENABLE-2;\nexpectations regarding the Company's growth, transition to late-stage\ndevelopment and commercialization, and the creation of long-term shareholder\nvalue; and statements by Enliven's Chief Executive Officer and a member of\nEnliven's Board of Directors. Forward-looking statements are based on current\nbeliefs and assumptions that are subject to risks and uncertainties and are\nnot guarantees of future performance. Actual results could differ materially\nfrom those contained in any forward-looking statement as a result of various\nrisks and uncertainties, including, without limitation the limited operating\nhistory of Enliven; relcobatinib failing to demonstrate sufficient safety,\nefficacy, tolerability, durability, differentiated attributes or therapeutic\nbenefit in current or future clinical trials; delays or difficulties in\nrecruiting, enrolling or maintaining patients in relcobatinib clinical trials;\nthe risks of delays in completing the ongoing ENABLE trial or initiating\nENABLE-2; Enliven failing to complete the ongoing ENABLE trial, to initiate\nENABLE-2 or to advance relcobatinib through clinical development; regulatory\nauthorities disagreeing with Enliven's clinical trial design, endpoints or\ninterpretation of data, or requiring additional studies or diagnostics;\ndevelopments relating to Enliven's competitors and industry which may affect\nthe development or potential market opportunity for relcobatinib; and the\npotential inability of Enliven to obtain regulatory approval for, or\nultimately commercialize or license, relcobatinib or other product candidates;\nEnliven's limited resources; Enliven's limited experience as a company in\ndesigning and conducting clinical trials; Enliven's lack of commercialization\nexpertise; the ability to attract, hire, and retain highly skilled executive\nofficers and employees; the ability of Enliven to protect its intellectual\nproperty and proprietary technologies; the scope of any patent protection\nEnliven obtains or the loss of any of Enliven's patent protection; reliance on\nthird parties, including medical institutions, contract manufacturing\norganizations, contract research organizations and strategic partners;\ngeopolitical developments, general market or macroeconomic conditions;\nEnliven's ability to obtain additional capital to fund Enliven's general\ncorporate activities and to fund Enliven's research and development; and other\nrisks and uncertainties more fully described in Enliven's filings with the\nSecurities and Exchange Commission (SEC), including under the heading \"Risk\nFactors\" in Enliven's Annual and Quarterly Reports on Form 10-K and Form 10-Q\nfiled with the SEC and in Enliven's future SEC filings. Except as required by\napplicable law, Enliven undertakes no obligation to revise or update any\nforward-looking statement, or to make any other forward-looking statements,\nwhether as a result of new information, future events or otherwise.\n\nThis press release contains hyperlinks to information that is not deemed to be\nincorporated by reference into this press release.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year-302909108.html\n(https://www.prnewswire.com/news-releases/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year-302909108.html)\n\nSOURCE Enliven Therapeutics, Inc.\n\n\n\nInvestors: ir@enliventherapeutics.com; Media: media@enliventherapeutics.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1618026/Enliven-Therapeutics-Logo.jpg?id=OA3019092\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnbfTd6qa-20261014","title":"Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year","author":"PR Newswire","ticker":"ELVN","created":"2026-10-14T20:30:01.487Z","tickers":["ELVN"],"exchange":"NASDAQ","article_body":"Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year\nPR Newswire\n\nBURLINGAME, Calif., Oct. 14, 2026\n\nAccomplished biopharmaceutical executive with extensive experience in\ncorporate strategy, finance and commercial readiness\n\nEnliven continues preparation for late-stage development and\ncommercialization, as it plans to initiate the pivotal Phase 3 trial of\nrelcobatinib before year-end\n\nBURLINGAME, Calif., Oct. 14, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=651038477&u=https%3A%2F%2Fwww.enliventherapeutics.com%2F&a=Enliven+Therapeutics%2C+Inc.)\n(Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical\ncompany focused on the discovery and development of small molecule\ntherapeutics, today announced the appointment of Kristine Ball to its Board of\nDirectors, effective immediately. Ms. Ball brings more than 20 years of\nexecutive experience across clinical-stage and commercial-stage\nbiopharmaceutical companies.\n\n\"We are pleased to welcome Kristine Ball to our Board,\" said Rick Fair, Chief\nExecutive Officer of Enliven. \"Her experience helping companies transition\nfrom clinical development to commercial operations will bring valuable\nperspective as we prepare to initiate our pivotal Phase 3 trial of\nrelcobatinib before year-end and plan for commercialization. We look forward\nto her contributions as we work to deliver a differentiated treatment option\nfor people living with chronic myeloid leukemia and create long-term value for\nour shareholders.\"\n\n\"Having seen the impact of CML on a member of my family, I feel a personal\nconnection to Enliven's mission of helping people with CML not only live\nlonger, but live better,\" said Ms. Ball. \"I'm excited to contribute as the\nCompany navigates this transition and prepares for potential\ncommercialization. I look forward to working with the Board and leadership\nteam to help advance relcobatinib through pivotal development and prepare\nEnliven for its next stage of growth.\"\n\nMs. Ball brings extensive executive leadership and financial expertise in the\nbiotechnology industry. Her experience spans corporate strategy, financing,\ncommercial readiness and corporate governance.  She has served as Chief\nExecutive Officer of Antiva Biosciences; Chief Executive Officer of Soteria\nBiotherapeutics; Senior Vice President of Corporate Strategy and Chief\nFinancial Officer of Menlo Therapeutics; and Senior Vice President and Chief\nFinancial Officer of Relypsa, where she helped guide the company's transition\nfrom clinical development to commercial operations. Additionally, she serves\non the Board of Directors of Oruka Therapeutics, where she chairs the Audit\nCommittee. She previously served on the boards of Atreca and Forty Seven. Ms.\nBall earned a Bachelor of Science from Babson College.\n\nFollowing its recent announcement of FDA alignment on the final design of\nENABLE-2, Enliven remains focused on initiating the pivotal Phase 3 trial of\nrelcobatinib (ELVN-001) in patients with previously treated chronic myeloid\nleukemia (CML) before year-end 2026.\n\nAbout Enliven Therapeutics\nEnliven is a clinical-stage biopharmaceutical company focused on the discovery\nand development of small molecule therapeutics to help people not only live\nlonger, but live better. Enliven aims to address existing and emerging unmet\nneeds with a precision medicine approach that improves survival and enhances\noverall well-being. Enliven's discovery process combines deep insights into\nclinically validated biological targets and differentiated chemistry to design\npotentially first-in-class or best-in-class therapies. Enliven is based in\nBurlingame, California. To learn more, visit www.enliventherapeutics.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=2498345477&u=http%3A%2F%2Fwww.enliventherapeutics.com%2F&a=www.enliventherapeutics.com)\nand connect with us on LinkedIn\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=3197493944&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4745046-1%26h%3D2856687620%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fenliventherapeutics%26a%3DLinkedIn&a=LinkedIn)\n and X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4797937-1&h=810257792&u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4745046-1%26h%3D3997352174%26u%3Dhttps%253A%252F%252Fx.com%252FEnliven_Tx%26a%3DX&a=X)\n.\n\nForward-Looking Statements\nThis press release contains forward-looking statements (including within the\nmeaning of Section 21E of the Securities Exchange Act of 1934, as amended, and\nSection 27A of the Securities Act of 1933, as amended) concerning Enliven and\nother matters that involve substantial risks and uncertainties. These\nstatements may discuss goals, intentions and expectations as to future plans,\ntrends, events, results of operations and financial condition, or otherwise,\nbased on current beliefs of Enliven's management, as well as assumptions made\nby, and information currently available to, Enliven's management.\nForward-looking statements generally include statements that are predictive in\nnature and depend upon or refer to future events or conditions, and include\nwords such as \"may,\" \"will,\" \"should,\" \"would,\" \"expect,\" \"anticipate,\"\n\"plan,\" \"likely,\" \"believe,\" \"estimate,\" \"project,\" \"intend,\" and other\nsimilar expressions or the negative or plural of these words, or other similar\nexpressions that are predictions or indicate future events or prospects,\nalthough not all forward-looking statements contain these words. Statements\nthat are not historical facts are forward-looking statements. Forward-looking\nstatements in this press release include, but are not limited to: statements\nregarding the potential of, and plans regarding, market opportunities,\ncommercial readiness, potential commercialization, and expectations regarding\nrelcobatinib (ELVN-001); statements regarding the potential differentiated\nattributes and therapeutic benefit of relcobatinib; the continued conduct,\ndesign and future clinical evaluation of relcobatinib, including the planned\nENABLE-2 Phase 3 trial and the potential timing of initiation of ENABLE-2;\nexpectations regarding the Company's growth, transition to late-stage\ndevelopment and commercialization, and the creation of long-term shareholder\nvalue; and statements by Enliven's Chief Executive Officer and a member of\nEnliven's Board of Directors. Forward-looking statements are based on current\nbeliefs and assumptions that are subject to risks and uncertainties and are\nnot guarantees of future performance. Actual results could differ materially\nfrom those contained in any forward-looking statement as a result of various\nrisks and uncertainties, including, without limitation the limited operating\nhistory of Enliven; relcobatinib failing to demonstrate sufficient safety,\nefficacy, tolerability, durability, differentiated attributes or therapeutic\nbenefit in current or future clinical trials; delays or difficulties in\nrecruiting, enrolling or maintaining patients in relcobatinib clinical trials;\nthe risks of delays in completing the ongoing ENABLE trial or initiating\nENABLE-2; Enliven failing to complete the ongoing ENABLE trial, to initiate\nENABLE-2 or to advance relcobatinib through clinical development; regulatory\nauthorities disagreeing with Enliven's clinical trial design, endpoints or\ninterpretation of data, or requiring additional studies or diagnostics;\ndevelopments relating to Enliven's competitors and industry which may affect\nthe development or potential market opportunity for relcobatinib; and the\npotential inability of Enliven to obtain regulatory approval for, or\nultimately commercialize or license, relcobatinib or other product candidates;\nEnliven's limited resources; Enliven's limited experience as a company in\ndesigning and conducting clinical trials; Enliven's lack of commercialization\nexpertise; the ability to attract, hire, and retain highly skilled executive\nofficers and employees; the ability of Enliven to protect its intellectual\nproperty and proprietary technologies; the scope of any patent protection\nEnliven obtains or the loss of any of Enliven's patent protection; reliance on\nthird parties, including medical institutions, contract manufacturing\norganizations, contract research organizations and strategic partners;\ngeopolitical developments, general market or macroeconomic conditions;\nEnliven's ability to obtain additional capital to fund Enliven's general\ncorporate activities and to fund Enliven's research and development; and other\nrisks and uncertainties more fully described in Enliven's filings with the\nSecurities and Exchange Commission (SEC), including under the heading \"Risk\nFactors\" in Enliven's Annual and Quarterly Reports on Form 10-K and Form 10-Q\nfiled with the SEC and in Enliven's future SEC filings. Except as required by\napplicable law, Enliven undertakes no obligation to revise or update any\nforward-looking statement, or to make any other forward-looking statements,\nwhether as a result of new information, future events or otherwise.\n\nThis press release contains hyperlinks to information that is not deemed to be\nincorporated by reference into this press release.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year-302909108.html\n(https://www.prnewswire.com/news-releases/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year-302909108.html)\n\nSOURCE Enliven Therapeutics, Inc.\n\n\n\nInvestors: ir@enliventherapeutics.com; Media: media@enliventherapeutics.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1618026/Enliven-Therapeutics-Logo.jpg?id=OA3019092\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-14T20:30:01.632581492Z","server_sent_at_ms":1792009801632},"received_at":"2026-10-14T20:30:01.683Z","source_url":"https://www.prnewswire.com/news-releases/enliven-therapeutics-appoints-kristine-ball-to-board-of-directors-ahead-of-planned-phase-3-trial-initiation-this-year-302909108.html"},"analysis":{"id":"157788","press_release_id":"169551","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Enliven Therapeutics appointed biopharma executive Kristine Ball to its Board of Directors, effective immediately.\n\nBall brings more than 20 years of experience, including CEO roles at Antiva Biosciences and Soteria Biotherapeutics and CFO tenures at Menlo Therapeutics and Relypsa, where she guided the clinical-to-commercial transition.\n\nThe appointment comes as Enliven prepares to initiate the pivotal Phase 3 ENABLE-2 trial of relcobatinib in previously treated CML patients before year-end 2026, following recent FDA alignment on the trial design.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Commercialization-focused board addition ahead of ENABLE-2 Phase 3 start — a governance signal for a company approaching late-stage development."},"keyFigures":{"drugName":"relcobatinib (ELVN-001)","phaseOfTrial":"Phase 3","customDimensions":{"indication":"previously treated chronic myeloid leukemia (CML)","trial_name":"ENABLE-2"}},"quotedText":"Her experience helping companies transition from clinical development to commercial operations will bring valuable perspective as we prepare to initiate our pivotal Phase 3 trial of relcobatinib before year-end and plan for commercialization.","namedEntities":{"people":[{"name":"Kristine Ball","role":"Board of Directors member (incoming)"},{"name":"Rick Fair","role":"CEO"}],"products":["relcobatinib","ELVN-001"],"companies":[{"name":"Enliven Therapeutics, Inc.","ticker":"ELVN","relationship":"filer"},{"name":"Antiva Biosciences","relationship":"Ball's prior CEO role"},{"name":"Soteria Biotherapeutics","relationship":"Ball's prior CEO role"},{"name":"Menlo Therapeutics","relationship":"Ball's prior CFO role"},{"name":"Relypsa","relationship":"Ball's prior CFO role"},{"name":"Oruka Therapeutics","relationship":"Ball's current board seat"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine board appointment adding commercialization expertise ahead of a Phase 3 initiation already announced. Positive signal but not market-moving on its own."},"tickerRelevance":{"others":[{"ticker":"ORKA","relevance":"board member's current other board seat (Oruka Therapeutics)"}],"primary":"ELVN"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"mid-cap-clinical-biotech","eventGravity":"board_addition","eventBackdrop":"Phase 3 initiation planned before year-end 2026","retailFavoriteBoost":false}},"event_type":"board_change","event_type_secondary":["clinical_trial"],"sentiment":"neutral","material_impact_score":2,"narrative":"Enliven Therapeutics appointed biopharma executive Kristine Ball to its Board of Directors, effective immediately.\n\nBall brings more than 20 years of experience, including CEO roles at Antiva Biosciences and Soteria Biotherapeutics and CFO tenures at Menlo Therapeutics and Relypsa, where she guided the clinical-to-commercial transition.\n\nThe appointment comes as Enliven prepares to initiate the pivotal Phase 3 ENABLE-2 trial of relcobatinib in previously treated CML patients before year-end 2026, following recent FDA alignment on the trial design.","key_figures":{"drugName":"relcobatinib (ELVN-001)","phaseOfTrial":"Phase 3","customDimensions":{"indication":"previously treated chronic myeloid leukemia (CML)","trial_name":"ENABLE-2"}},"named_entities":{"people":[{"name":"Kristine Ball","role":"Board of Directors member (incoming)"},{"name":"Rick Fair","role":"CEO"}],"products":["relcobatinib","ELVN-001"],"companies":[{"name":"Enliven Therapeutics, Inc.","ticker":"ELVN","relationship":"filer"},{"name":"Antiva Biosciences","relationship":"Ball's prior CEO role"},{"name":"Soteria Biotherapeutics","relationship":"Ball's prior CEO role"},{"name":"Menlo Therapeutics","relationship":"Ball's prior CFO role"},{"name":"Relypsa","relationship":"Ball's prior CFO role"},{"name":"Oruka Therapeutics","relationship":"Ball's current board seat"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T20:30:10.185Z","global_importance":22,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap-clinical-biotech","eventGravity":"board_addition","eventBackdrop":"Phase 3 initiation planned before year-end 2026","retailFavoriteBoost":false}},"durationMs":4770,"modelName":"glm-5.3-flashx"}}